Advaxis climbs after FDA lifts clinical hold

Advaxis Inc. (NASDAQ:ADXS) gained $2.62 (32%) to $10.92 on Wednesday after FDA lifted a clinical hold on INDs for cancer products axalimogene filolisbac ( ADXS11-001), ADXS-PSA, and ADXS- HER2. The hold affected nine clinical trials.

Advaxis agreed to revise the studies' inclusion and exclusion critiera, post-administration antibiotic treatment and patient surveillance measures. ...